The SURMOUNT trials used weekly tirzepatide dosing exclusively and showed average weight loss of 22.5% at the highest dose
If the impurities are confirmed by independent laboratories, the case for separating B12 from tirzepatide becomes overwhelming
Finally, over half of the of participants discontinued the medications, and this number was slightly higher for participants taking tirzepatide
The decision to switch is personalized, considering individual health profiles, weight loss goals, lifestyle, and cost-effectiveness, ensuring the most suitable and affordable approach for each patient
However, discontinuation without maintaining lifestyle changes may lead to weight regain
Under this rule, a qualified medical expense is one that diagnoses, treats, mitigates, or prevents a disease